Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rudy J. Castellani is active.

Publication


Featured researches published by Rudy J. Castellani.


Journal of Neuropathology and Experimental Neurology | 2006

Involvement of Oxidative Stress in Alzheimer Disease

Akihiko Nunomura; Rudy J. Castellani; Xiongwei Zhu; Paula I. Moreira; George Perry; Mark A. Smith

Genetic and lifestyle-related risk factors for Alzheimer disease (AD) are associated with an increase in oxidative stress, suggesting that oxidative stress is involved at an early stage of the pathologic cascade. Moreover, oxidative stress is mechanistically and chronologically associated with other key features of AD, namely, metabolic, mitochondrial, metal, and cell-cycle abnormalities. Contrary to the commonly held notion that pathologic hallmarks of AD signify etiology, several lines of evidence now indicate that aggregation of amyloid-&bgr; and tau is a compensatory response to underlying oxidative stress. Therefore, removal of proteinaceous accumulations may treat the epiphenomenon rather than the disease and may actually enhance oxidative damage. Although some antioxidants have been shown to reduce the incidence of AD, the magnitude of the effect may be modified by individual factors such as genetic predisposition (e.g. apolipoprotein E genotype) and habitual behaviors. Because caloric restriction, exercise, and intellectual activity have been experimentally shown to promote neuronal survival through enhancement of endogenous antioxidant defenses, a combination of dietary regimen of low total calorie and rich antioxidant nutrients and maintaining physical and intellectual activities may ultimately prove to be one of the most efficacious strategies for AD prevention.


Annals of the New York Academy of Sciences | 2005

Oxidative Stress and Neurodegeneration

Paula I. Moreira; Mark A. Smith; Xiongwei Zhu; Akihiko Nunomura; Rudy J. Castellani; George Perry

Abstract: Oxidative stress is a well‐studied early response in chronic neurodegenerative diseases, including Alzheimers disease, where neuronal loss can exceed 90% in the vulnerable neuronal population. Oxidative stress affects all classes of macromolecules (sugar, lipids, proteins, and DNA), leading inevitably to neuronal dysfunction. We observed that Nε‐(carboxymethyl)lysine (CML), the predominant advanced glycation end product that accumulates in vivo, along with its glycation‐specific precursor hexitol‐lysine, are increased in neurons from cases of Alzheimers disease, especially those containing intracellular neurofibrillary pathology. The increase in hexitol‐lysine and CML can result from either lipid peroxidation or advanced glycation, whereas hexitol‐lysine is solely a product of glycation, suggesting that two distinct oxidative processes act in concert in the neuropathology of the disease. Furthermore, using olfactory neurons as an experimental model, we observed an increase in glycation products in neurons derived from Alzheimers disease patients. Our findings support the idea that aldehyde‐mediated modifications, in concert with oxyradical‐mediated modifications, are critical early pathogenic factors in Alzheimers disease.


Journal of Neuroscience Research | 2002

Role of mitochondrial dysfunction in Alzheimer's disease.

Rudy J. Castellani; Keisuke Hirai; Gjumrakch Aliev; Kelly L. Drew; Akihiko Nunomura; Atsushi Takeda; Adam D. Cash; Mark E. Obrenovich; George Perry; Mark A. Smith

Abnormalities in mitochondrial function relate to the spectrum of pathological changes seen in Alzheimers disease. Here we review the causes and consequences of mitochondrial disturbances in Alzheimers disease as well as how this information might impact on therapeutic approaches to this disease.


Brain Research | 1996

Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease.

Rudy J. Castellani; Mark A. Smith; Peggy L. Richey; George Perry

Oxidative stress is well accepted as an important pathogenic factor in Parkinson disease, based largely on indirect evidence. Recently, we have developed antibodies that recognize specific advanced glycation end-products (anti-pentosidine and anti-pyrraline), protein modifications that are potentiated by oxidative stress in a process termed glycoxidation. We applied these antibodies immunocytochemically to affected regions in Parkinson disease and diffuse Lewy body disease brains. Additionally, we used antibodies to heme oxygenase-1, a putative marker of oxidative stress response. Immunoreactivity to pentosidine, pyrraline, and heme oxygenase-1 was seen in the substantia nigra of Parkinson disease and the neocortex of diffuse Lewy body disease. Heme oxygenase-1 was further demonstrated by immunoelectron microscopy in intimate association with filaments of cortical Lewy bodies. Immunolocalization of advanced glycation end-products and a marker of oxidative stress response induction provides evidence that glycoxidation and oxidative stress may be an important pathogenic factor in diseases characterized by Lewy body formation, and furthers the evidence that cytoskeletal proteins and their inclusions are susceptible to oxidative stress.


American Journal of Pathology | 2003

Microtubule Reduction in Alzheimer's Disease and Aging Is Independent of τ Filament Formation

Adam D. Cash; Gjumrakch Aliev; Akihiko Nunomura; Hisashi Fujioka; Xiongwei Zhu; Arun K. Raina; Harry V. Vinters; Massimo Tabaton; Anne B. Johnson; Manuel Paula-Barbosa; Jesús Avila; Paul K. Jones; Rudy J. Castellani; Mark A. Smith; George Perry

Biochemical studies show that phosphorylated tau, like that found in paired helical filaments (PHFs), does not promote microtubule assembly leading to the view that PHF formation leads to microtubule deficiency in Alzheimers disease (AD). However, although this issue is one of the most important aspects to further understanding the cell biology of AD, no quantitative examination of microtubule diminution in AD and its relationship with PHFs has been performed. To examine this issue directly, we undertook a morphometric study of brain biopsy specimens from AD and control cases. Ultrastructural analysis of neurons was performed to compare the microtubule assembly state in neurons of diseased and control cases and to examine the effect of PHF accumulation. We found that both number and total length of microtubules were significantly and selectively reduced in pyramidal neurons from AD in comparison to control cases (P = 0.000004) but that this decrement in microtubule density was surprisingly unrelated to PHFs (P = 0.8). Further, we found a significant age-dependent decrease in microtubule density with aging in the control cases (P = 0.016). These findings suggest that reduction in microtubule assembly is not dependent on tau abnormalities of AD and aging.


British Journal of Sports Medicine | 2017

Consensus statement on concussion in sport-the 5th international conference on concussion in sport held in Berlin, October 2016

Paul McCrory; Willem H. Meeuwisse; Jiri Dvorak; Mark Aubry; Julian E. Bailes; Steven P. Broglio; Robert C. Cantu; David Cassidy; Ruben J. Echemendia; Rudy J. Castellani; Gavin A. Davis; Richard G. Ellenbogen; Carolyn A. Emery; Lars Engebretsen; Nina Feddermann-Demont; Christopher C. Giza; Kevin M. Guskiewicz; Grant L. Iverson; Karen M. Johnston; James Kissick; Jeffrey S. Kutcher; John J. Leddy; David Maddocks; Michael Makdissi; Geoff T. Manley; Michael McCrea; William P. Meehan; Shinji Nagahiro; Jonathan Speridon Patricios; Margot Putukian

The 2017 Concussion in Sport Group (CISG) consensus statement is designed to build on the principles outlined in the previous statements1–4 and to develop further conceptual understanding of sport-related concussion (SRC) using an expert consensus-based approach. This document is developed for physicians and healthcare providers who are involved in athlete care, whether at a recreational, elite or professional level. While agreement exists on the principal messages conveyed by this document, the authors acknowledge that the science of SRC is evolving and therefore individual management and return-to-play decisions remain in the realm of clinical judgement. This consensus document reflects the current state of knowledge and will need to be modified as new knowledge develops. It provides an overview of issues that may be of importance to healthcare providers involved in the management of SRC. This paper should be read in conjunction with the systematic reviews and methodology paper that accompany it. First and foremost, this document is intended to guide clinical practice; however, the authors feel that it can also help form the agenda for future research relevant to SRC by identifying knowledge gaps. A series of specific clinical questions were developed as part of the consensus process for the Berlin 2016 meeting. Each consensus question was the subject of a specific formal systematic review, which is published concurrently with this summary statement. Readers are directed to these background papers in conjunction with this summary statement as they provide the context for the issues and include the scope of published research, search strategy and citations reviewed for each question. This 2017 consensus statement also summarises each topic and recommendations in the context of all five CISG meetings (that is, 2001, 2004, 2008, 2012 as well as 2016). Approximately 60 000 published articles were screened by the expert panels for the Berlin …


Journal of Neurochemistry | 2002

Induction of Heme Oxygenase‐1 mRNA and Protein in Neocortex and Cerebral Vessels in Alzheimer's Disease

Daniel R. D. Premkumar; Mark A. Smith; Peggy L. Richey; Robert B. Petersen; Rudy J. Castellani; R. Krishnan Kutty; Barbara Wiggert; George Perry; Rajesh N. Kalaria

Abstract: Previous studies demonstrated the specific association of heme oxygenase (HO)‐1 protein to the neurofibrillary pathology of Alzheimers disease (AD). In this study, we used reverse transcription‐polymerase chain reaction methods to show the increased expression of HO‐1 but not HO‐2 mRNA transcripts in cerebral cortex and cerebral vessels from subjects with AD compared with age‐matched non‐AD controls. Neither the HO‐1 nor the HO‐2 mRNA level was altered in the cerebellum, a brain region usually spared from the pathological alterations of AD. There was no clear evidence that the expression of HO‐1 in these tissues was related to postmortem interval, cause of death, or the age of the subjects studied. Using immunoblotting methods, we further showed that HO‐1 protein content was increased in neocortical and vascular samples from AD subjects compared with controls. Our findings suggest the specific induction of HO‐1 mRNA and protein in the cerebral cortex and cerebral vessels but not HO‐2 mRNA or protein in association with the pathological lesions of the disease.


Free Radical Biology and Medicine | 2001

Active glycation in neurofibrillary pathology of Alzheimer disease: Nε-(Carboxymethyl) lysine and hexitol-lysine

Rudy J. Castellani; Peggy L.R. Harris; Lawrence M. Sayre; Junichi Fujii; Naoyuki Taniguchi; Michael P. Vitek; Hank Founds; Craig S. Atwood; George Perry; Mark A. Smith

Abstract Advanced glycation end products are a diverse class of posttranslational modifications, stemming from reactive aldehyde reactions, that have been implicated in the pathogenesis of a number of degenerative diseases. Because advanced glycation end products are accelerated by, and result in formation of, oxygen-derived free radicals, they represent an important component of the oxidative stress hypothesis of Alzheimer disease (AD). In this study, we used in situ techniques to assess N e -(Carboxymethyl)lysine (CML), the predominant advanced glycation end product that accumulates in vivo, along with its glycation-specific precursor hexitol-lysine, in patients with AD as well as in young and aged-matched control cases. Both CML and hexitol-lysine were increased in neurons, especially those containing intracellular neurofibrillary pathology in cases of AD. The increase in hexitol-lysine and CML in AD suggests that glycation is an early event in disease pathogenesis. In addition, because CML can result from either lipid peroxidation or advanced glycation, while hexitol-lysine is solely a product of glycation, this study, together with studies demonstrating the presence of 4-hydroxy-2-nonenal adducts and pentosidine, provides evidence of two distinct oxidative processes acting in concert in AD neuropathology. Our findings support the notion that aldehyde-mediated modifications, together with oxyradical-mediated modifications, are critical pathogenic factors in AD.


Journal of Alzheimer's Disease | 1998

Reactive Oxygen Species Mediate Cellular Damage in Alzheimer Disease

George Perry; Rudy J. Castellani; Keisuke Hirai; Mark A. Smith

The two most striking features of Alzheimer disease are (i) the multitude of abnormalities affecting essentially every system and (ii) the strict age dependence. Recent work suggests that both features are linked to increased oxidative stress that damages lipids, proteins and nucleic acids and results in redox-active metal accumulations, mitochondrial damage and formation of advanced glycation endproducts. Interestingly, beta-protein precursor, amyloid-beta, presenilins, and apolipoprotein E have all been linked to reactive oxygen species production or apoptosis, a process intimately associated with oxidative stress. In therapeutics, the commonality between a number of efficacious agents appears to be oxidative stress reduction. Therefore, we contend that oxidative stress is the element that links the multitude of changes in Alzheimer disease and that a reduction of oxidative stress will have a dramatic effect on reducing the incidence or progression of Alzheimer disease.


Acta Neuropathologica | 2000

Sequestration of iron by Lewy bodies in Parkinson's disease.

Rudy J. Castellani; George Perry; Mark A. Smith

Abstract Central to the oxidative stress hypothesis of Parkinson’s disease (PD) pathogenesis is the ability of iron to generate hydroxyl radicals via the Fenton reaction, and the consistent demonstration of iron elevation in the pars compacta region of the substantia nigra. However, uncertainty exists as to whether the excess iron exists in a state suitable for redox chemistry. Here, using a method we developed that detects redox-active iron in situ, we were able to demonstrate strong labeling of Lewy bodies in substantia nigra pars compacta neurons in PD. In contrast, cortical Lewy bodies in cases of Lewy body variant of Alzheimer’s disease were unstained. While the presence of elevated iron in PD substantiates the oxidative stress hypothesis, one must remember that these are viable neurons, indicating that Lewy bodies may act to sequester iron in PD brains in a protective, rather than degenerative, mechanism. The absence of redox-active iron in neocortical Lewy bodies highlights a fundamental difference between cortical and brain stem Lewy bodies.

Collaboration


Dive into the Rudy J. Castellani's collaboration.

Top Co-Authors

Avatar

George Perry

University of Texas at San Antonio

View shared research outputs
Top Co-Authors

Avatar

Mark A. Smith

Case Western Reserve University

View shared research outputs
Top Co-Authors

Avatar

Xiongwei Zhu

Case Western Reserve University

View shared research outputs
Top Co-Authors

Avatar

Hyoung Gon Lee

Case Western Reserve University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Peggy L.R. Harris

Case Western Reserve University

View shared research outputs
Top Co-Authors

Avatar

Robert B. Petersen

Case Western Reserve University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mark A. Smith

Case Western Reserve University

View shared research outputs
Researchain Logo
Decentralizing Knowledge